FABENTECH

Companies & groups

Founded in 2009, Fabentech specialises in the development and production of broad-spectrum therapeutics for fighting high-priority biological agents which could threaten public health.

Our platform is based on a safe, tested and fully validated polyclonal antibody technology, initially developed by Sanofi Pasteur and enhanced by the Fabentech R&D team for more than a decade. Our Integrated R&D and proprietary manufacturing site enable rapid developments of medical countermeasures against different targets. We are using our expertise to offer reliable protection and treatments ready to face proliferating risks.
Fabentech’s mission is to collaborate closely with governments and healthcare organisations, providing timely and effective medical countermeasures to combat highly pathogenic agents during public health crises. We help nations to build robust preparedness plans that enable effective anticipation and response to potential future pandemics and bioterror attacks.

055505446104-20

Lyon

FR

business_company

French joint-stock company